Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
Clinical trial NCT05148884 · COMPLETED
Trial details
- NCT number
- NCT05148884
- Sponsor
- Neurolixis SAS
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-09
- Primary completion
- 2023-01-18
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.